Select your Market

Global
Africa
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
Congo
Congo Democratic Republic
Djibouti
Egypt
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Ivory Coast
Kenya
Lesotho
Liberia
Libya
Madagascar
Malawi
Mauritania
Mauritius
Morocco
Mozambique
Namibia
Niger
Nigeria
Reunion Islands
Rwanda
Saint Helena
São Tomé and Príncipe
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
Sudan
Swaziland
Tanzania
Togo
Tunisia
Uganda
Zambia
Zimbabwe
Asia
Bahrain
Bangladesh
China, mainland
India
Indonesia
Iran
Iraq
Israel
Japan
Jordan
Kuwait
Lebanon
Malaysia
Oman
Palestine
Philippines
Qatar
Saudi Arabia
Singapore
South Korea
Syria
Taiwan
Thailand
Turkey
United Arab Emirates
Vietnam
Yemen
Europe
Albania
Austria
Baltic Region
Belarus
Belgium
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Luxembourg
Netherlands
North Macedonia
Norway
Poland
Portugal
Romania
Russian Federation
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Türkiye
Ukraine
United Kingdom
Latin America
Argentina
Aruba
Bahamas
Barbados
Belize
Bolivia
Brazil
Central America
Chile
Colombia
Costa Rica
Cuba
Curacao-NL Antillen
Ecuador
El Salvador
Guatemala
Haiti
Honduras
Jamaica
Mexico
Nicaragua
Panama
Paraguay
Perú
República Dominicana
Trinidad and Tobago
Uruguay
Venezuela
North America
Canada
United States of America
Oceania
Australia
New Zealand
Global

We are committed to developing new medicines for patients impacted by difficult-to-treat diseases as safely and quickly as possible. We believe the best way to fulfill this commitment is through clinical studies that evaluate whether our investigational products are safe and effective, which can lead to the medicine being approved and made available to the broadest number of patients possible. Once a product is approved, we continue to evaluate our marketed products by monitoring real world data and engaging in post-marketing clinical trials.

Our clinical trials follow high medical and ethical standards, in accordance with the principles laid down in the Declaration of Helsinki, and are consistent with Good Clinical Practice and applicable local laws and regulations. 

By making clinical trial information available, we are:

  • Informing patients, investigators and healthcare professionals about the clinical research we sponsor.
  • Promoting the distribution of knowledge and minimizing the risk of duplication of research efforts.
  • Supporting the publication of full manuscripts in peer-reviewed journals.
  • Contributing towards transparency and building mutual trust.

For more information: click here

Information available for researchers

Healthcare will make data from completed clinical trials publicly available within six months following the occurrence of all the following events:

  • Approval of a product or a new indication by major health authorities, including the FDA, EMA, and PMDA (if requested), with no pending submission plans.
  • Public availability of study results through the primary manuscript scientific publication or a disclosure on a clinical trial registry.
  • Establishment of legal authority to share the data.
  • Implementation of measures to ensure the protection of participant privacy.

If approval of a product is not sought or Healthcare has globally discontinued the development of the product for all indications and has no plans for future development, Healthcare shall make public the availability of such data within eighteen months after the global trial completion date. Requests from Healthcare’s competitors outside Industry collaboration initiatives shall not be granted. Requests relating to products approved before January 1, 2014, and requests for legacy or discontinued compounds are reviewed through the same process. Clinical Trials in scope of our Responsible Data Sharing Commitment are listed on our clinical trials website. 

Interested Researchers?

Qualified researchers may request access to individual patient or aggregate level data from a Merck-sponsored study by submitting a research proposal to https://vivli.org.

Learn more about our standards for conducting clinical trials around the world under Positions & Policies. 

EXTERNAL RESOURCES

US/NPR/0517/0230(1)a(1)c(1)